EMERGENT BIOSOLUTIONS INC. (NYSE:EBS) Files An 8-K Results of Operations and Financial Condition

EMERGENT BIOSOLUTIONS INC. (NYSE:EBS) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.

On January 7, 2019, Emergent BioSolutions Inc. announced preliminary unaudited financial results for 2018 and guidance for 2019. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In addition, the sections entitled “Track Record of Profitable, Diversified Growth,” “2018 Performance,” and “Reconciliation Tables” of the corporate slide deck attached as Exhibit 99.2 are incorporated herein by reference.
Story continues below

Item 7.01Regulation FD Disclosure.

During the week of January 7, 2019, representatives of the company will be attending meetings with investors, analysts and others at the J.P. Morgan Healthcare Conference in San Francisco, California and these company representatives plan to present the slides attached as Exhibit 99.2 to this Current Report on Form 8-K.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.

ExhibitNo.

Description

99.1

Press release, issued January 7, 2019.

99.2

Corporate slide deck, dated January 8, 2019.

Emergent BioSolutions Inc. Exhibit
EX-99.1 2 exhibit99_1.htm                                                                                                          EXHIBIT 99.1   EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2018 FINANCIAL RESULTS AND PROVIDES 2019 FINANCIAL FORECAST · Full year 2018 preliminary performance in line with recently revised guidance · Full year 2019 forecast reflects continued growth of organic business and anticipated positive impact of recent acquisitions GAITHERSBURG,…
To view the full exhibit click here

About EMERGENT BIOSOLUTIONS INC. (NYSE:EBS)

Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics in areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Its two operating divisions include Biodefense and Biosciences. The Biodefense division is a pharmaceutical business focused on countermeasures that address public health threats, including chemical, biological, radiological, nuclear and explosives (CBRNE) threats, as well as EID. The Biosciences division is a pharmaceutical business focused on therapeutics in hematology/oncology with secondary on transplantation, infectious disease and autoimmunity.

An ad to help with our costs